EquityZen Growth Technology Fund LLC - Series 2296
Raised
$875K
Investors
42
Min Invest
$10,024
AltStreet Analysis
·Generated from EDGAR primary sources
EquityZen Growth Technology Fund LLC - Series 2296 is a Delaware pooled investment fund that raised $875K from 42 investors under Rule 506(b) and Section 3(c)(1) exemptions, with a $10K minimum investment. Filed May 20, 2026 by EquityZen Advisors and Philip Haslett, this is one of approximately 1,889 related entities in the EquityZen pre-IPO secondary marketplace platform.
This pre-IPO fund follows the standard EquityZen series structure: a 506(b) private placement with 3(c)(1) investment company exemption, accessible to accredited investors at a $10K entry point. The sub-$1M raise and 42-investor count are consistent with single-company SPVs designed for secondary share access in private technology companies.
Data Flags
EDGAR Filing Data
Form D — Primary Source
View on SEC.govRelated Persons (Form D)
Executive officers, directors, and promoters listed on the SEC Form D filing. Source: SEC.gov.
EquityZen Advisors LLC
Executive Officer, Director · New York, NY
Philip Haslett
Executive Officer, Director · New York, NY
Is this your offering?
Claim this profile to add contact information, team members, LinkedIn profiles, fund history, and additional financial data. EDGAR-sourced data and AltStreet analysis cannot be edited, but corrections can be requested for verifiable inaccuracies.
Data Methodology
Capital raise figures, investor counts, and filing dates are sourced directly from SEC EDGAR Form D primary documents via the SEC EDGAR submissions API and full-text search index. EDGAR entity profiles and deal-level data are reviewed by AltStreet analysts with backgrounds in corporate finance and securities law — cross-referenced against offering circulars, audited financial statements, and primary regulatory filings before publication. Platform-provided information, where present, is clearly labeled and does not affect EDGAR data or AltStreet editorial coverage. Platforms may request factual corrections for demonstrable inaccuracies by contacting [email protected]. This page does not constitute investment advice.
